NCT00436163View on ClinicalTrials.gov

A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Peginterferon alfa-2a

180 mcg subcutaneously once per week for 48 weeks.

Trial Locations (9)

1006

Riga

10138

Tallinn

10617

Tallinn

47144

Kaunas

50009

Kaunas

51014

Tartu

92288

Klaipėda

08117

Vilnius

08661

Vilnius

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00436163 - A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B | Biotech Hunter | Biotech Hunter